World malaria report 2013 shows major progress in fight against malaria, calls for sustained financing

11 December 2013 | Geneva/Washington DC - Global efforts to control and eliminate malaria have saved an estimated 3.3 million lives since 2000, reducing malaria mortality rates by 45% globally and by 49% in Africa, according to the "World malaria report 2013" published by WHO.

An expansion of prevention and control measures has been mirrored by a consistent decline in malaria deaths and illness, despite an increase in the global population at risk of malaria between 2000 and 2012. Increased political commitment and expanded funding have helped to reduce incidence of malaria by 29% globally, and by 31% in Africa.

The large majority of the 3.3 million lives saved between 2000 and 2012 were in the 10 countries with the highest malaria burden, and among children aged less than 5 years – the group most affected by the disease. Over the same period, malaria mortality rates in children in Africa were reduced by an estimated 54%.

But more needs to be done.

“This remarkable progress is no cause for complacency: absolute numbers of malaria cases and deaths are not going down as fast as they could,” says Dr Margaret Chan, WHO Director-General. “The fact that so many people are infected and dying from mosquito bites is one of the greatest tragedies of the 21st century.”

In 2012, there were an estimated 207 million cases of malaria (uncertainty interval: 135 – 287 million), which caused approximately 627?000 malaria deaths (uncertainty interval 473?000 – 789?000). An estimated 3.4 billion people continue to be at risk of malaria, mostly in Africa and south-east Asia. Around 80% of malaria cases occur in Africa.

Long way from universal access to prevention and treatment

Malaria prevention suffered a setback after its strong build-up between 2005 and 2010. The new WHO report notes a slowdown in the expansion of interventions to control mosquitoes for the second successive year, particularly in providing access to insecticide-treated bed nets. This has been primarily due to lack of funds to procure bed nets in countries that have ongoing malaria transmission.

In sub-Saharan Africa, the proportion of the population with access to an insecticide-treated bed net remained well under 50% in 2013. Only 70 million new bed nets were delivered to malaria-endemic countries in 2012, below the 150 million minimum needed every year to ensure everyone at risk is protected. However, in 2013, about 136 million nets were delivered, and the pipeline for 2014 looks even stronger (approximately 200 million), suggesting that there is real chance for a turnaround.

There was no such setback for malaria diagnostic testing, which has continued to expand in recent years. Between 2010 and 2012, the proportion of people with suspected malaria who received a diagnostic test in the public sector increased from 44% to 64% globally.

Access to WHO-recommended artemisinin-based combination therapies (ACTs) has also increased, with the number of treatment courses delivered to countries rising from 76 million in 2006 to 331 million in 2012.

Despite this progress, millions of people continue to lack access to diagnosis and quality-assured treatment, particularly in countries with weak health systems. The roll-out of preventive therapies – recommended for infants, children under 5 and pregnant women – has also been slow in recent years.

“To win the fight against malaria we must get the means to prevent and treat the disease to every family who needs it,” says Raymond G Chambers, the United Nations Secretary General’s Special Envoy for Financing the Health MDGs and for Malaria. "Our collective efforts are not only ending the needless suffering of millions, but are helping families thrive and adding billions of dollars to economies that nations can use in other ways.”

Global funding gap

International funding for malaria control increased from less than US$ 100 million in 2000 to almost US$ 2 billion in 2012. Domestic funding stood at around US$ 0.5 billion in the same year, bringing the total international and domestic funding committed to malaria control to US$ 2.5 billion in 2012 – less than half the US$ 5.1 billion needed each year to achieve universal access to interventions.

Without adequate and predictable funding, the progress against malaria is also threatened by emerging parasite resistance to artemisinin, the core component of ACTs, and mosquito resistance to insecticides. Artemisinin resistance has been detected in four countries in south-east Asia, and insecticide resistance has been found in at least 64 countries.

“The remarkable gains against malaria are still fragile,” says Dr Robert Newman, Director of the WHO Global Malaria Programme. “In the next 10-15 years, the world will need innovative tools and technologies, as well as new strategic approaches to sustain and accelerate progress.”

WHO is currently developing a global technical strategy for malaria control and elimination for the 2016-2025 period, as well as a global plan to control and eliminate Plasmodium vivax malaria. Prevalent primarily in Asia and South America, P. vivax malaria is less likely than P. falciparum to result in severe malaria or death, but it generally responds more slowly to control efforts. Globally, about 9% of the estimated malaria cases are due to P. vivax, although the proportion outside the African continent is 50%.

"The vote of confidence shown by donors last week at the replenishment conference for the Global Fund to Fight AIDS, Tuberculosis and Malaria is testimony to the success of global partnership. But we must fill the annual gap of US$ 2.6 billion to achieve universal coverage and prevent malaria deaths," said Fatoumata Nafo-Traore, Executive Director of the Roll Back Malaria Partnership. "This is our historic opportunity to defeat malaria."

Notes for editors:

The "World malaria report 2013" summarizes information received from 102 countries that had on-going malaria transmission during the 2000-2012 period, and other sources, and updates the analyses presented in 2012.

The report contains revised estimates of the number of malaria cases and deaths, which integrate new and updated under-5 mortality estimates produced by the United Nations Inter-agency Group for Child Mortality Estimation, as well as new data from the Child Health Epidemiology Reference Group.

For more information, please contact:

In Geneva
Fadela Chaib
WHO Communications Officer/Spokesperson
Telephone: +41 22 791 3228
Mobile: +41 79 475 5556
E-mail: chaibf@who.int

In Washington DC
Phil Coticelli
Telephone: +1 301 801 5801
E-mail: phil@coticelligroup.com

View the original article here

Advances in nanotechnology's fight against cancer

Dec. 19, 2013 — As cancer maintains its standing as the second leading cause of death in the U.S., researchers have continued their quest for safer and more effective treatments. Among the most promising advances has been the rise of nanomedicine, the application of tiny materials and devices whose sizes are measured in the billionths of a meter to detect, diagnose and treat disease.

A new research review co-authored by a UCLA professor provides one of the most comprehensive assessments to date of research on nanomedicine-based approaches to treating cancer and offers insight into how researchers can best position nanomedicine-based cancer treatments for FDA approval.

The article, by Dean Ho, professor of oral biology and medicine at the UCLA School of Dentistry, and Edward Chow, assistant professor at the Cancer Science Institute of Singapore and the National University of Singapore, was published online by the peer-reviewed journal Science Translational Medicine. Ho and Chow describe the paths that nanotechnology-enabled therapies could take -- and the regulatory and funding obstacles they could encounter -- as they progress through safety and efficacy studies.

"Manufacturing, safety and toxicity studies that will be accepted by the Food and Drug Administration before clinical studies are just some of the considerations that continue to be addressed by the nanomedicine field," said Chow, the paper's co-corresponding author.

Compared with other available therapies, nanomedicine has proven to be especially promising in fighting cancer. In preclinical trials, nanomaterials have produced safer and more effective imaging and drug delivery, and they have enabled researchers to precisely target tumors while sparing patients' healthy tissue. In addition, nanotechnology has significantly improved the sensitivity of magnetic resonance imaging, making hard-to-find cancers easier to detect.

"A broad spectrum of innovative vehicles is being developed by the cancer nanomedicine community for targeted drug delivery and imaging systems," said Dr. Ho, the paper's corresponding author and co-director of the Jane and Jerry Weintraub Center for Reconstructive Biotechnology at the UCLA School of Dentistry. "It is important to address regulatory issues, overcome manufacturing challenges and outline a strategy for implementing nanomedicine therapies -- both individually and in combination -- to help achieve widespread acceptance for the clinical use of cancer nanomedicine."

Ho's team previously pioneered the development of a nanodiamond-doxorubicin compound named NDX. In preclinical studies conducted with Chow, NDX was found to be safer and more effective than unmodified doxorubicin, a clinical standard, for treating breast, liver and other cancer models.

Ho and Chow's new report features multiple studies in which the use of nanoparticles was translated from the preclinical to the clinical stage. In several of the highlighted studies, nanotechnology-modified drugs showed improvements over conventional, drug-only approaches because of their ability to overcome drug resistance (which occurs when tumors reject the drug and stop responding to treatment), to more effective tumor reduction, among other advantages.

The authors also describe how algorithm-based methods that rapidly determine the best drug combinations, and computation-based methods that draw information from databases of drug interactions and side effects, to help rationally design drug combinations could potentially be paired with nanomedicine to deliver multiple nano-therapies together to further improve the potency and safety of cancer treatments.

"This research review by Dr. Ho and his colleagues lays the groundwork for nanomedicine to become a widely accepted cancer therapy," said Dr. No-Hee Park, dean of the UCLA School of Dentistry. "This blueprint for navigating the process from bench research to mainstream clinical use is invaluable to the nanotechnology community."

Dr. Ho, also a professor of bioengineering and a member of the Jonsson Comprehensive Cancer Center and California NanoSystems Institute, noted that nanomedicine regulation is still in its early stages, but the clinical use of existing nanoparticle drugs, such as the protein-modified breast cancer drug Abraxane, is a promising start.

"The FDA's approval of Abraxane provides a strong foundation for the continued acceleration of new cancer nanomedicine therapies and imaging solutions in the fight against cancer," Ho said.

View the original article here

How to discover drugs, such as thalidomide to fight cancer

Causes of congenital defect of the 50 despite the tragic legacy of two years ago, thalidomide - new drugs derived from it - as an effective treatment for patients with multiple myeloma and other cancers. How it slows down the spread of cancer action, however the long description of the rebellious. In a new report, Dana Farber Cancer Institute scientists found that kill multiple myeloma cells by mechanisms different from the way their drug birth defects cause and says.

View the original article here

Typhoon babies fight against odds in ravaged Philippine city

By Stuart Grudgings

TACLOBAN, Philippines (Reuters) - In the chapel of the only functioning public hospital in typhoon-ravaged Tacloban, seven tiny, premature babies lie sweltering in intense heat, looked over by anxious mothers and a wooden statue of Christ.

An eighth, born two days after Friday's monster storm hit the central Philippines, is kept alive only by his exhausted grandmother who pumps air by hand into his sick lungs. Only one baby, his face bruised purple from a hurried delivery by forceps, is strong enough to cry.

The others are eerily quiet as they battle to survive in a hospital without power, clean water, and running out of essential medical supplies.

It remains the only medical option in the city of Tacloban for most survivors of Typhoon Haiyan, which may have killed thousands of people. The storm destroyed all but two hospitals in the city, one of them private.

"Our immediate problems are immense," said Dr. Alberto de Leon, the 62-year-old director of the hospital, the Eastern Visayas Regional Medical Center, adding he nearly lost his own life in the surge of ocean water that accompanied Haiyan.

Caught unawares by the wall of water that engulfed the city of 220,000 on Friday morning, he clung to a refrigerator as the living room of his single-storey home filled almost to the ceiling.

At the entrance of the hospital, next to a sign asking people to take bodies straight to the morgue, urgent needs are listed on a makeshift sign: a generator, drinking water, oxygen, cooking gas, medicine and manpower.

A single gasoline-fuelled generator is the only source of power, leaving patients to sweat in dark corridors as they await treatment from a wide range of wounds caused by the churning, debris-packed seawater.

That also means there is no way to stop the bodies of 18 victims of the typhoon from decomposing in the morgue.

"I'm worried the newborns will get hospital-acquired infections," said de Leon. "The cadavers at the back could be a source."

Many of the 80 babies born in the hospital since the typhoon came prematurely, their mothers shocked into labor by Friday's trauma. In the chapel, a tangle of intravenous drips and oxygen has been planted between the pews to keep the newborns alive, but basic medicines are running short, nurses said.

The mostly Roman Catholic Philippines has one of Asia's highest birth rates, particularly in poorer areas such as the central Visayas region.

Nanette Salutan, 40, went into premature labor hours after the storm blew the roof off her house in a small town near Tacloban.

She then endured a two-hour ride on the back of a motorbike, dodging fallen trees and electricity poles, before giving birth by flashlight in the hospital early on Saturday.

Heavily pregnant Mary Jane Tevez, 16, and her husband escaped from their own collapsing house on Friday only to be trapped in the rapidly crumbling home of a neighbor. She began feeling unbearable pain in her pelvis even as they fought for their lives by sheltering under thick plywood.

Their baby boy was born early on Saturday. Its name? Yolando, the masculine version of Typhoon Haiyan's Philippine name Yolanda.

"It's because we don't want to forget what we had to go through and because we got another life," said his father, Meller Balabog.

(Editing by Dean Yates)

View the original article here

AIDS fight enters new phase with prevention pill

AppId is over the quota
AppId is over the quota

CHICAGO (AP) — Condoms and other safe-sex practices have accomplished only so much. Now the 30-year battle against AIDS is on the verge of a radical new phase, with the government expected to endorse a once-a-day pill to prevent infection with the virus.

Some doctors are already giving patients the drug, Truvada, to ward off infection. But Food and Drug Administration approval would expand that practice and could make the highly expensive medicine more affordable. Truvada costs around $11,000 to $14,000 a year.

Approval seems likely after an FDA advisory panel Thursday endorsed the use of Truvada for prevention.

In the generation-long fight against AIDS, "it's the first time we have talked about a medication for prevention of HIV," said Dr. Lisa Sterman of Francisco, who treats HIV-positive patients.

"With this recommendation, we're nearing a watershed moment in our fight against HIV," said James Loduca, a spokesman for the San Francisco AIDS Foundation. "We know this isn't a magic bullet, and it's not going to be the right prevention strategy for everyone, but it could save thousands of lives in the United States and potentially millions around the world."

Truvada has been FDA-approved since 2004 for treating people infected with the AIDS virus. Once a drug is on the market, doctors are free to prescribe it for off-label, or unapproved, uses, and that's what some have been doing in giving Truvada to patients who are healthy but in danger of getting the virus from their partners or through risky sex.

Official FDA backing of the practice would allow Truvada's maker, Gilead Sciences Inc. of Foster City, Calif., to market it for prevention. Approval would also probably lead many more insurance companies to pay for the drug. And by widening the market for Truvada, it could prompt Gilead to lower the price.

An FDA decision is expected by June 15.

The FDA is also considering approving the first over-the-counter HIV test for use at home. Experts said it could help slow the spread of HIV.

An estimated 1.2 million Americans and millions more around the world have HIV. Unless the virus is treated with antiviral drugs, it can turn into full-blown AIDS. Antivirals have made the disease more manageable and allowed patients to live much longer than when the epidemic began in the early 1980s.

Nevertheless, about 50,000 new infections are diagnosed in the U.S. each year, a number that has held steady for about 15 years.

Truvada represents "a pretty radical step, but I think it's a necessary step," said Sterman, who prescribes it to infected patients and those who are healthy but at risk. "We've come as far as we can with condom use and safe-sex strategies."

The drug would be recommended for people at high risk of getting the virus, such as gay men with multiple sex partners, prostitutes and people whose partners are infected.

In one U.S. government study of more than 1,200 men and women in Botswana, Truvada lowered the HIV infection risk by about 78 percent. Another larger study in Africa found a slightly lower rate of effectiveness, but researchers say that if used as directed, the pill can be 90 percent effective or higher.

It is available as an HIV treatment in Africa and other poor regions, but Gilead is seeking approval for prevention in the U.S. only, a company spokeswoman said. Some experts have expressed concern that the use of Truvada for prevention could cause shortages in poor countries that desperately need the drug to treat infected people.

Not everyone in the HIV community is gung-ho about the drug.

Michael Weinstein, president of the AIDS Healthcare Foundation, a Los Angeles-based group that calls itself the nation's largest provider of medical care for HIV, said his main concern is that patients won't take the drug as directed — once a day, while also using condoms. Misuse could create drug-resistant HIV strains and lead to more infections.

The FDA panelists acknowledged that concern and said people should be tested to make sure they don't have HIV before starting Truvada. Patients who already have the virus could develop resistance to the drug.

As for the drug's high cost, generic Truvada for HIV treatment is available in poor countries for as little as $9 per month, a Gilead spokeswoman said. But generic versions are not available in the United States and won't be until after Truvada's U.S. patent expires in 2021. Sterman said she hopes FDA approval leads Gilead to lower the price.

The lifetime cost of treating one person diagnosed with the AIDS virus has been estimated at more than $600,000.

"It's much more cost-effective to prevent a new infection than it is to treat someone for their lifetime," Loduca said. "Of course, the ultimate goal is a vaccine and a cure, but we're many years away from that."

Some of the more serious complications linked to Truvada include kidney and liver problems. But for some people, the risk of kidney problems "10 years down the line may be less than the risk for acquiring HIV, which is significantly more problematic and can be fatal," said Jim Pickett, director of prevention advocacy at the AIDS Foundation of Chicago.

Nick Literski, a government employee in Seattle, has been taking Truvada for HIV prevention for more than a year because his partner is infected. He said the drug has helped prevent the breakup of relationships like his.

"Many HIV-positive men end up ending their relationships with HIV-negative men out of fear of infecting their partner," Literski said.

___

AP Health Writer Matthew Perrone contributed to this story from Washington.

___

Online:

FDA: http://www.fda.gov

AIDS: http://www.aids.gov

___

AP Medical Writer Lindsey Tanner can be reached at http://www.twitter.com/LindseyTanner

Exclusive: China amends patent law in fight for cheaper drugs

AppId is over the quota
AppId is over the quota

HONG KONG (Reuters) - China has overhauled parts of its intellectual property laws to allow its drugmakers to make cheap copies of medicines still under patent protection in a move likely to unnerve foreign pharmaceutical companies.

The Chinese move comes within months of a similar move by India to effectively end the monopoly on an expensive cancer drug made by Bayer AG by issuing its first so-called "compulsory license".

Similar action by China will ring alarm bells in Big Pharma, since the country is a vital growth market at a time when sales in Western countries are flagging.

The amended Chinese patent law allows Beijing to issue compulsory licenses to eligible companies to produce generic versions of patented drugs during state emergencies, or unusual circumstances, or in the interests of the public.

For "reasons of public health", eligible drugmakers can also ask to export these medicines to other countries, including members of the World Trade Organisation.

Compulsory licenses are available to nations to issue under WTO rules in certain cases where life-saving treatments are unaffordable.

"The revised version of Measures for the Compulsory Licensing for Patent Implementation came into effect from May 1, 2012," China's State Intellectual Property Office said in a faxed statement to Reuters.

The changes can be found on the website of China's State Intellectual Property Office at http://www.sipo.gov.cn/.

China is known to be looking at Gilead Sciences Inc's tenofovir, which is recommended by the World Health Organisation as part of a first-line cocktail treatment for AIDS patients, two sources with direct knowledge of the matter said.

China's generic drugmakers were getting ready to produce tenofovir, they added.

At a drug access workshop hosted by the United Nations and health activists in Bangkok in early June, Chinese officials spoke of the changes to its patent law. Officials from Cambodia, India, Indonesia, Malaysia, Myanmar, the Philippines, Thailand and Vietnam also participated in the meeting.

"In May 2012, China created a change in their IPR (intellectual property rights) legislation to be able to issue compulsory licenses. China is considering further strengthening its legal framework, so as to make use of legal space to produce generic drugs," said Bob Verbruggen, senior adviser for the UNAIDS Asia Pacific office, who was present at the workshop.

"China's action plan at the workshop seemed to confirm that it intends to become a generic producer for the domestic and international market," he told Reuters by telephone.

CHINA PREPARED LONG AND HARD FOR THIS

China's move follows India's granting of a compulsory license in March to local generic drugs firm Natco Pharma to manufacture Bayer's cancer drug Nexavar, used for treating kidney and liver cancer.

However, China had signaled interest in the idea from at least 2008-2009, when its State Intellectual Property Office invited foreign experts to Beijing to show Chinese officials how to prepare the legal grounds for issuing compulsory licenses.

"They wanted to know the legal perspective ... They wanted to know about Thailand's IP Act that allowed us to make a CL (compulsory license) under the law for public interests, in an emergency," said Vithaya Kulsomboon, associate professor at Thailand's Chulalongkorn University, who was invited to Beijing at the time.

Kajal Bhardwaj, a legal expert from India who is working on health, HIV and human rights trade laws, said China's move was well within the limits of international trade agreements.

"CLs have previously been issued in the region by Malaysia, Indonesia, Thailand and India. CLs have also been issued on multiple occasions by developed countries including the U.S. and EU member countries," Bhardwaj said.

"It is very encouraging that China is seeking to ensure that this right ... is reflected in its legal regime on intellectual property," she added.

SABRE-RATTLING

China's stable of generic drugmakers has been producing the key ingredients - or active pharmaceutical ingredients (APIs) - in medicines for years, exporting them to foreign drugmakers, which then sell the patented finished products back to China at prices which the average Chinese citizen often cannot afford.

In particular, the government is struggling to provide newer HIV drugs, such as Gilead's tenofovir, known by its brand Viread and which had worldwide sales last year of $737.9 million.

China's government, initially slow to acknowledge the problem of HIV/AIDS in the 1990s, now admits to having a ballooning number of HIV/AIDS cases.

Although Gilead moved to share its intellectual property rights on its medicines in a patent pool with generic drugmakers from many countries last July in return for a small royalty, China was excluded, which meant it had to continue paying high prices for tenofovir.

Since the change in China's patent law, Gilead has offered certain concessions, including giving China a substantial donation of tenofovir if it continues to buy the same amount, said Paul Cawthorne, coordinator for Medecins Sans Frontieres' Access Campaign in Asia.

"This is all a negotiation game; this offer from Gilead came about once the news that the Chinese was considering issuing a CL came out. The end game is okay, you get a better deal or you use the CL, it's a strategy that many countries use," he said.

Gilead in Hong Kong declined to comment. No one was immediately available to comment at its head office in California.

All eyes are now trained on how China battles it out with big foreign drug exporters, especially from 2013 when the Geneva-based Global Fund to Fight AIDS, Tuberculosis and Malaria will no longer give grants to China to fight HIV.

(Reporting by Tan Ee Lyn in Hong Kong and Beijing newsroom; Additional reporting by Ben Hirschler in London; Editing by Anne Marie Roantree and David Cowell)

Immunology strengthens the fight against Colon Cancer Stage 4

Immunotherapy is undoubtedly a new medical strategy that evokes the human immune system to eradicate the disease. To summarize, in a span of 30 years, focusing the research conducted by both teams of doctors and scientists has shown that this approach is clinically successful for a wide range of diseases. Advances in adoptive immunotherapy, which focuses on expanding and infusion of specific disease-fighting white blood cells in patients, fast have followed this scientific arena its peak in terms of being an effective treatment for viral diseases, colon cancer, and surprisingly even stage 4 cancer types.

We can suppose, taking into consideration the reliable results and continuous progress, the importance of immunotherapy to grow exponentially-especially as it applies to late stage colon and other Stage 4 cancer. Currently, colon cancer stage 4 targets with little more than chemo and radiation, so the statistics are grim ... Renowned care providers do not dare report data of survival beyond the first couple of years as it is disappointing, with marginal promise.

New immunotherapy treatments, however, are inspiring as they provide an essential part of the puzzle-treatment with better overall results collaborated and quality of life for patients.

Envita leads the field in stage 4 Colon Cancer

A string of results published are shown the effects of adoptive immuno therapy in cancer patients. Dedicated medical team of Envita has evaluated the most reliable studies said and given the strengths and weaknesses of each. Their Immaculate research requires a protocol that incorporates only the most effective procedures for the extension and application of cells as a powerful immunotherapy. Our protocols are based on the latest published literature in the arena, by many hospitals and universities most prestigious both nationally and globally. Predictably, our treatment has been specially formulated specifically to treat colon cancer and immune systems of cancer patients in 4 phases.

Of Envita Colon Cancer 4 dual phase and immunotherapy of cancer 4th stage

Natural Envita Medical Center established in Mexico is using NK and CTL cells in real-time as immunotherapy for treatment of cancer and stage 4 colon cancer. Immune therapy of proprietary vaccine Envita appropriately is labelled AAIT\R (for immune system therapy autologous foster), and there are 4 main types of cells involved-the most significant being natural killer cells and T cells. The following are the types of cells that make up the treatment of Envita:

= > ‧ Natural killer cells
= > ‧ Natural killer t cells
‧ Cytokine Induced > = killer cells
= ‧ Cytotoxic T lymphocytes >

The being was created with the expansion of a patient's own immune cells in antitumor mega amounts. These cells are then analyzed for activation indicators and highlighted for their ability to destroy the colon cancer and other cells in the laboratory under controlled conditions, and then re-infused into the patient.

AAIT\R immunology available for Colon cancer and Stage 4 cancer patients to Mexico Envita

Natural Envita Medical Center is currently using T lymphocytes, NK and NKT as support for immunotherapy of cancer patients. Proprietary Envita vaccine stage 4 colon cancer is recorded as AAIT\R-one who increases a patient's own cancer cells of the immune system in the billions in a span of several weeks. These cells are evaluated for indicators, analysed for their ability to neutralize tumor cells stage 4 colon cancer in the lab and then eventually re-infused into the patient. Heralded by scientific research and clinical results of AAIT\R immunotherapy Enivta presents a valuable option for cancer patients who are acutely dedicated to conquering colon cancer stage 4 and others, while a intact immune system balance. Envita administers only top-level combinations of conventional cancer treatment and alternative accentuated by advanced cancer treatment natural help patients secure better health and improve the overall quality of life.

Understanding Stage 4 cancer is vital for those patients seeking remission of cancer at any stage. Recognizing necessary approaches, you will improve your chances of remission, the quality and length of life. Patients involved with the most comprehensive treatment plans always respond better to treatment. Let Envita better tailor prostate cancer Stage 4 treatment plan in place for you.

Use and distribution of this article is subject to our Publisher guidelines
whereby the original author and copyright information must be included.